Related Experiment Video
Updated: Oct 25, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
miR-425-5p as an exosomal biomarker for metastatic prostate cancer
Michele Patrícia Rode1, Adny Henrique Silva1, Júlia Cisilotto1
1Department of Pharmaceutical Sciences, Federal University of Santa Catarina, Florianópolis, SC 88040-900, Brazil.
Abstract:
Prostate cancer-related deaths are mostly caused by metastasis, which indicates the importance of identifying clinical prognostic biomarkers. In this study, we evaluated the expression profile of exosomal microRNAs (miRNAs) derived from metastatic prostate cancer (mPCa) cell lines (LNCaP and PC-3). miRNA signatures in exosomes and cells were evaluated by miRNA microarray analysis. Fourteen miRNAs were identified as candidates for specific noninvasive biomarkers. The expression of five miRNAs was validated using RT-qPCR, which confirmed that miR-205-5p, miR-148a-3p, miR-125b-5p, miR-183-5p, and miR-425-5p were differentially expressed in mPCa exosomes. Bioinformatic analyses showed that miR-425-5p was associated with residual tumor, pathologic T and N stages, and TP53 status in PCa samples. Gene ontology analysis of negatively correlated and predicted targeted genes showed enrichment of genes related to bone development pathways. The LinkedOmics database indicated that the potential target HSPB8 has a significant negative correlation with miR-425-5p. In conclusion, this study identified a panel of exosomal miRNAs with potential value as prognostic biomarkers for prostate cancer.
Insights
Researchers identified specific exosomal microRNAs (miRNAs) as potential noninvasive prognostic biomarkers for metastatic prostate cancer (mPCa). These miRNA signatures could aid in predicting patient outcomes and guiding treatment strategies for advanced prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Prostate cancer metastasis is a primary cause of mortality.
- Identifying reliable prognostic biomarkers is crucial for managing metastatic prostate cancer (mPCa).
- Exosomal microRNAs (miRNAs) are emerging as promising noninvasive biomarkers.
Purpose of the Study:
- To identify and validate exosomal miRNA signatures as prognostic biomarkers for mPCa.
- To explore the association of specific miRNAs with clinical parameters in prostate cancer.
- To investigate potential molecular pathways regulated by identified miRNAs.
Main Methods:
- Exosomal miRNAs were isolated from mPCa cell lines (LNCaP, PC-3).
- miRNA expression profiling was performed using microarray analysis.
- RT-qPCR was used to validate the expression of candidate miRNAs.
- Bioinformatic and database analyses (LinkedOmics) were employed to predict miRNA targets and functions.
Main Results:
- Fourteen candidate exosomal miRNAs were identified.
- Five miRNAs (miR-205-5p, miR-148a-3p, miR-125b-5p, miR-183-5p, miR-425-5p) were differentially expressed in mPCa exosomes.
- miR-425-5p showed associations with residual tumor, pathologic T and N stages, and TP53 status.
- Enrichment analysis suggested involvement in bone development pathways, with HSPB8 identified as a potential target of miR-425-5p.
Conclusions:
- A panel of exosomal miRNAs has been identified as potential prognostic biomarkers for prostate cancer.
- These exosomal miRNAs may offer noninvasive tools for predicting patient prognosis in mPCa.
- Further research is warranted to elucidate the functional roles and clinical utility of these biomarkers.
